Gemini Therapeutics is a biotechnology company focused on developing precision medicines for genetically defined subpopulations affected by dry age-related macular degeneration (AMD) and related diseases. The company operates in the biopharmaceutical market, targeting common but poorly understood heterogeneous diseases. Gemini Therapeutics employs a therapeutic approach that leverages recombinant proteins, gene therapy, and monoclonal antibodies to create effective treatments. The business model revolves around identifying specific therapeutic candidates through scientific insights and conducting natural history studies to define target populations. Revenue is generated through the development and commercialization of these targeted therapies. The company serves patients suffering from dry AMD and related conditions, aiming to bring better medicine to millions of people worldwide.

Keywords: precision medicine, dry AMD, gene therapy, monoclonal antibodies, recombinant proteins, biopharmaceutical, therapeutic candidates, genetically defined subpopulations, heterogeneous diseases, natural history studies.